Moreover, by leveraging a lentivirus to boost VTN expression within the PANC02 pancreatic cancer cell line in mice and subsequently crafting a subcutaneous tumor model, we observed an amplified therapeutic response when coupled with anti-PD1 administration. The gene discussed is VTN; the disease is familial pancreatic carcinoma.